ベイジーン、進行性/転移性胃がん、食道胃接合部がん、食道扁平上皮がんの一次治療薬となるTEVIMBRA®について、CHMPが肯定的見解を採択
カリフォルニア州、サンマテオ (ビジネスワイヤ) —...
View ArticleZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC),...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation...
View ArticleQurient Launches Clinical Trial for Acute Myeloid Leukemia Treatment with...
SEONGNAM, South Korea Qurient Co. Ltd. (KRX: 115180) has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug...
View ArticleLabGenomics USA Completes Acquisition of IMD CLIA Labs
ROCKVILLE, Md. LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, bringing the total number of its CLIA-certified labs in the U.S. to four. This acquisition...
View ArticleBeiGene Mourns Death of Beloved Board Member Donald Glazer
SAN MATEO, Calif. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and...
View ArticleDelta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML...
TOKUSHIMA, Japan Following to the previous information on September 10th. 2024, we are excited to share our latest development status. Enrollment of patients is progressing smoothly into the Phase I...
View ArticleTempus Announces Collaboration With JW Pharmaceutical to Apply Real-World...
CHICAGO Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with JW Pharmaceutical, one of the most established pharmaceutical companies in Korea, to...
View Articleベイジーン、大切な取締役ドナルド・グレイザー氏の死を悼む
カリフォルニア州、サンマテオ (ビジネスワイヤ) — がん領域におけるグローバル企業であるベイジーン(NASDAQ:BGNE、HKEX:06160、SSE:688235)は、ドナルド・グレイザー氏が先ごろ逝去されたことをお知らせします。同氏は取締役会のメンバーであり、指名・コーポレートガバナンス委員会の委員長を務めました。...
View ArticleZai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy...
View ArticleUS FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar...
SHANGHAI, China & JERSEY CITY, N.J. Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has accepted the Biologic License...
View ArticlebioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
SAN ANTONIO bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung...
View ArticleThree Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated...
TOKYO & BASKING RIDGE, N.J. The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)-based...
View Article